
Neuroplasticity by Prescription: How Motivista Unlocks Negative Symptoms in Schizophrenia
Dr. Dereck Mush, MD, MBADeveloper of prescription digital therapeutics, including Motivista for negative symptoms of schizophrenia.
Motivista, also known as CT-155, is a prescription digital therapeutic for negative symptoms of schizophrenia in adults with clinically stable positive symptoms. It is used alongside clinician-managed outpatient care, including antipsychotics. FDA granted 510(k) clearance in October 2026 following the Phase III CONVOKE study. Click describes it as the first FDA-authorised treatment for that indication. Boehringer Ingelheim's April 2026 investment also transferred full product responsibility and commercial and marketing authorisation rights to Click.
Leadership as of 14 November 2026.
Founder & CEO
How Click Therapeutics got here, step by step.
2024
FDA granted Breakthrough Device Designation to CT-155.
9 April 2026
Boehringer Ingelheim made a $50M Series D strategic investment plus dedicated commercial funding and transferred full product responsibility for CT-155, including commercial and marketing authorisation rights, to Click.
5 October 2026
510(k) clearance for Motivista, a prescription digital therapeutic for negative symptoms of schizophrenia; the company says it is the first FDA-authorised treatment for that indication. Supported by the Phase III CONVOKE study.
5 October 2026
FDA clears Motivista (CT-155)9 April 2026
Click Therapeutics and Boehringer Ingelheim announce Series D investment
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBATopic: Prescription digital therapeutics

Dr. Dereck Mush, MD, MBATopic: Prescription digital therapeutics
Related companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: